359 related articles for article (PubMed ID: 35299253)
1. Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Choe PG; Hong J; Park J; Chang E; Kang CK; Kim NJ; Lee CH; Park WB; Oh MD
J Infect Dis; 2022 Sep; 226(7):1224-1230. PubMed ID: 35299253
[TBL] [Abstract][Full Text] [Related]
2. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
[TBL] [Abstract][Full Text] [Related]
4. Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 - A Comprehensive Analysis.
Meyer B; Martinez-Murillo PA; Lemaitre B; Blanchard-Rohner G; Didierlaurent AM; Fontannaz P; Eugercios Manzanas C; Lambert PH; Loevy N; Kaiser L; Sartoretti J; Tougne C; Villard J; Huttner A; Siegrist CA; Eberhardt CS
Front Immunol; 2022; 13():841009. PubMed ID: 35585978
[TBL] [Abstract][Full Text] [Related]
5. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
Mariën J; Ceulemans A; Michiels J; Heyndrickx L; Kerkhof K; Foque N; Widdowson MA; Mortgat L; Duysburgh E; Desombere I; Jansens H; Van Esbroeck M; Ariën KK
J Virol Methods; 2021 Feb; 288():114025. PubMed ID: 33227340
[TBL] [Abstract][Full Text] [Related]
6. Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19.
Liu WD; Wang JT; Chao TL; Ieong SM; Tsai YM; Kuo PH; Tsai MJ; Chen YJ; Li GC; Ho SY; Chen HH; Huang YS; Hung CC; Chen YC; Chang SY; Chang SC
J Formos Med Assoc; 2023 Aug; 122(8):714-722. PubMed ID: 36496300
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
[TBL] [Abstract][Full Text] [Related]
8. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of Different Classes and Subclasses of Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and CoronaVac Vaccination in Thailand.
Poolchanuan P; Matsee W; Sengyee S; Siripoon T; Dulsuk A; Phunpang R; Pisutsan P; Piyaphanee W; Luvira V; Chantratita N
mSphere; 2023 Feb; 8(1):e0046522. PubMed ID: 36688637
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
Demers-Mathieu V; DaPra C; Medo E
Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835
[No Abstract] [Full Text] [Related]
11. Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection.
Wright PF; Prevost-Reilly AC; Natarajan H; Brickley EB; Connor RI; Wieland-Alter WF; Miele AS; Weiner JA; Nerenz RD; Ackerman ME
J Infect Dis; 2022 Sep; 226(7):1204-1214. PubMed ID: 35188974
[TBL] [Abstract][Full Text] [Related]
12. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
[TBL] [Abstract][Full Text] [Related]
13. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
14. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand.
Tandhavanant S; Koosakunirand S; Kaewarpai T; Piyaphanee W; Leaungwutiwong P; Luvira V; Chantratita N
PLoS One; 2021; 16(8):e0255796. PubMed ID: 34375345
[TBL] [Abstract][Full Text] [Related]
16. Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis.
Ruiz MJ; Siracusano G; Cottignies-Calamarte A; Tudor D; Real F; Zhu A; Pastori C; Capron C; Rosenberg AR; Temperton N; Cantoni D; Liao H; Ternette N; Moine P; Godement M; Geri G; Chiche JD; Annane D; Cramer Bordé E; Lopalco L; Bomsel M
Front Immunol; 2022; 13():842468. PubMed ID: 36248831
[TBL] [Abstract][Full Text] [Related]
17. Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
Upasani V; Townsend K; Wu MY; Carr EJ; Hobbs A; Dowgier G; Ragno M; Herman LS; Sharma S; Shah D; Lee SFK; Chauhan N; Glanville JM; Neave L; Hanson S; Ravichandran S; Tynan A; O'Sullivan M; Moreira F; Workman S; Symes A; Burns SO; Tadros S; Hart JCL; Beale RCL; Gandhi S; Wall EC; McCoy L; Lowe DM
Clin Infect Dis; 2023 Oct; 77(7):950-960. PubMed ID: 37338118
[TBL] [Abstract][Full Text] [Related]
18. RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers.
Aguilar R; Li X; Crowell CS; Burrell T; Vidal M; Rubio R; Jiménez A; Hernández-Luis P; Hofmann D; Mijočević H; Jeske S; Christa C; D'Ippolito E; Lingor P; Knolle PA; Roggendorf H; Priller A; Yazici S; Carolis C; Mayor A; Schreiner P; Poppert H; Beyer H; Schambeck SE; Izquierdo L; Tortajada M; Angulo A; Soutschek E; Engel P; Garcia-Basteiro A; Busch DH; Moncunill G; Protzer U; Dobaño C; Gerhard M
Microbiol Spectr; 2023 Feb; 11(1):e0316522. PubMed ID: 36622140
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
Front Immunol; 2022; 13():830710. PubMed ID: 35173741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
